HiberCell logo

HiberCell

Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality.1 HiberCell seeks to change that. As “the dormancy company,” HiberCell is the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy. Toward this goal HiberCell is developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers. HiberCell's ultimate goal is to prevent or delay the recurrence of cancer.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.hibercell.com
Founded2019
Disease Focus
Development Stage
STOCK CODENon Listed
Address
619 West 54th Street, 8th Floor, NY, 10019
New York
United States
Email
Contact Number
+1 212-601-2800

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/hibercell” connections=”true” suffix=””]